ABCG2: determining its relevance in clinical drug resistance. - Wikidata - awgldk - TriplyDB

ABCG2: determining its relevance in clinical drug resistance.

ABCG2: determining its relevance in clinical drug resistance.

http://www.wikidata.org/entity/Q36745478

about

Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma Mechanisms of drug resistance in colon cancer and its therapeutic strategies Overcoming multidrug resistance via photodestruction of ABCG2-rich extracellular vesicles sequestering photosensitive chemotherapeutics Structure and function of ABCG2-rich extracellular vesicles mediating multidrug resistance Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies Long noncoding RNAs in the progression, metastasis, and prognosis of osteosarcoma Cancer stem cell metabolism: a potential target for cancer therapy MiRNAs and miRNA Polymorphisms Modify Drug Response Expression levels of the ABCG2 multidrug transporter in human erythrocytes correspond to pharmacologically relevant genetic variations New inhibitors of ABCG2 identified by high-throughput screening Botryllamides: natural product inhibitors of ABCG2 Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay.Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer.The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.Synthesis and structure-activity relationship of botryllamides that block the ABCG2 multidrug transporter Fluorescence resonance energy transfer (FRET) analysis demonstrates dimer/oligomer formation of the human breast cancer resistance protein (BCRP/ABCG2) in intact cells.Pluronics and MDR reversal: an update.Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).A selective ATP-binding cassette subfamily G member 2 efflux inhibitor revealed via high-throughput flow cytometry.Kinetic analysis of intracellular Hoechst 33342--DNA interactions by flow cytometry: misinterpretation of side population status?Substrate affinity of photosensitizers derived from chlorophyll-a: the ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynamic therapy.ABC multidrug transporters: structure, function and role in chemoresistance.Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence.Rapid detection of ABC transporter interaction: potential utility in pharmacology.The challenge of exploiting ABCG2 in the clinic.A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells.ABCG2: a perspective.WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells.ABC transporters: unvalidated therapeutic targets in cancer and the CNS Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia.ABCG2 localizes to the nucleus and modulates CDH1 expression in lung cancer cells Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter Three-dimensional structure of the human breast cancer resistance protein (BCRP/ABCG2) in an inward-facing conformation.

P2860

Q24649754-09D8B216-5F1E-4CDD-A348-D9B964904254 Q26738528-1547C06B-9704-4A4C-9DD8-A663B9A97CE4 Q27304425-9C85DC8A-4321-4C32-8EC9-D39414698006 Q27437985-93A4E795-1179-4050-98C1-31C9783C66F0 Q27694658-E8075C72-1B3A-4764-8456-26BD5FEC3011 Q27851688-B4E16C01-3D32-400E-9BB7-D40C3B288A2C Q28067499-C9F56A0F-5140-41BB-A08F-B73897FACC47 Q28072875-EBDB4855-7CC9-4F3F-9F21-E87C59C71EA9 Q28079045-3D81C279-DB17-493F-BC58-5D3604129209 Q28079075-66434669-A221-4CFE-BF68-32EA09C984EA Q28485221-8C1D2D52-2F83-44E3-8BF4-134339FCA736 Q33311099-D6A4AAF9-76D7-42A5-9AE7-23347293C1A5 Q33474489-2541CB37-7E34-4DE7-83D0-89AA0443E196 Q33476723-E14707E7-490D-448D-9448-6524DEC690DF Q33566582-6520F935-8066-4DD8-B6BC-78414BC5FE4B Q33566627-C8CE7004-282A-4877-A377-6A4DE0866782 Q33753716-D21DCE0F-1D95-4A8A-BCA3-C60DB0F44DCB Q33763765-2445CB8E-2BC0-47C9-98FF-4B0C1574FE8F Q33764532-6623135E-6C81-408E-962A-1F0A9DC4EE0D Q33980380-7EE84D23-7F05-47EA-A799-4E93FAA3352C Q34005678-E207B214-2806-4D00-B05D-7735DFFEBD4C Q34176588-AB38DCA0-FA77-46A2-BD5A-1E253D38BE41 Q34393952-3CDB2280-A618-4566-8272-2775C1A6B284 Q34470778-C2FAA7F9-7518-404A-8F40-DB20E1EA6215 Q34472249-FDAB22B9-A022-41A7-BEAF-5A088D272E2B Q34586418-31CC73AD-7C00-4F8F-BAF9-15981A7B339B Q34774854-4CE0707F-A344-403B-98E5-F38D98263F06 Q34897883-3FB2674F-0AC2-4784-8D74-CC40ACFE96DE Q34913068-C26B53A8-A0A6-4FF1-B255-17E9AAA57F5C Q34968909-93CF168E-1457-4703-A1AC-34059CCA503A Q34977187-F0543B01-BC80-4C09-AE48-149F03575636 Q35016817-53A056A3-E72B-4955-8414-3F65006408A1 Q35051599-DAC013DB-9F57-41B1-B939-A259D9CA46E5 Q35056738-A6C4F46F-2737-4E1F-B829-875633D08F83 Q35186322-EACA8B09-6A9E-46C1-A281-DAE418366B84 Q35214554-C3EB5EBB-CDAA-46A8-B34D-9C04F729D27F Q35588356-D96D56B2-36AA-423E-B064-4BF88AC821AB Q35612803-5C4E09DC-5750-4C25-BB88-8373C44E7D0E Q35674430-1249D768-D1B2-4D2B-81F2-FA65F8550E57 Q35927508-B71CA94F-7FB5-4D50-98F3-71DF83449F84

P2860

ABCG2: determining its relevance in clinical drug resistance.

http://www.wikidata.org/entity/Q36745478

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

ABCG2: determining its relevance in clinical drug resistance.

@ast

ABCG2: determining its relevance in clinical drug resistance.

@en

type

label

ABCG2: determining its relevance in clinical drug resistance.

@ast

ABCG2: determining its relevance in clinical drug resistance.

@en

prefLabel

ABCG2: determining its relevance in clinical drug resistance.

@ast

ABCG2: determining its relevance in clinical drug resistance.

@en

P1433

Q36745478-01C0FA62-9384-4297-BD65-B3F695D2D0A9

P1476

Q36745478-57ACDDBD-FB71-4D04-916E-F93F9360B5CF

P2093

Q36745478-1EC5E4CC-E411-4D52-A41F-131753611990

Q36745478-5C225E1F-6FDC-47C3-9C61-3BAE1A716CDF

Q36745478-89DCFC6A-497B-40DF-8A9B-A5C157F00186

Q36745478-938D32CD-8CCA-4C85-B958-621452B05A1A

Q36745478-BA1CDDA3-77B3-4ADE-8531-4C1637E854FB

P2860

Q36745478-05948A96-0CC7-4481-A6F9-4FBEC746DAD1

Q36745478-196BADFE-EEFE-49BD-9AAF-B6F7F2978D51

Q36745478-254E759F-DE7B-40D5-9304-310BBF431AE6

Q36745478-3EFC3B71-B89D-4E8B-A93F-9A225D13B894

Q36745478-4F867FC1-57C3-49CB-9895-EC66DF9E56FE

Q36745478-F149C4E2-95F2-4BEA-9B2C-9964A22E963B

P2888

Q36745478-36824F69-E30F-4968-BE48-3AECEA89FD7F

P304

Q36745478-8B97F4CC-4C95-4F05-9902-1164753417EB

P31

Q36745478-0A808697-D192-4FC0-8A6E-4CE2145F7952

P356

Q36745478-8129B773-2AD5-4ED9-9C56-F33DEBD3324D

P433

Q36745478-AC77F655-C210-47CD-881E-30254D18A42C

P478

Q36745478-963BB9CD-4A68-46F5-80C6-5BDF080E2211

P577

Q36745478-290DF7C2-64A7-44BA-88B2-6FFF3B3D3BE1

P698

Q36745478-A14C108B-BFDA-463C-8388-F59C50411444

P356

S10555-007-9042-6

P1433

Cancer and Metastasis Reviews

P1476

ABCG2: determining its relevance in clinical drug resistance.

@en

P2093

John Deeken

http://www.w3.org/2001/XMLSchema#string

Kin Wah To

http://www.w3.org/2001/XMLSchema#string

Orsolya Polgar

http://www.w3.org/2001/XMLSchema#string

Robert W Robey

http://www.w3.org/2001/XMLSchema#string

Susan E Bates

http://www.w3.org/2001/XMLSchema#string

P2860

Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene.

Side population cells and Bcrp1 expression in lung.

Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.

Expression of multidrug resistance-related transporters in human breast carcinoma.

Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.

P2888

s10555-007-9042-6

P304

39-57

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10555-007-9042-6

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17323127

http://www.w3.org/2001/XMLSchema#string